Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Immunological Reviews · 2023-11 · 320 (1) · 217-235
DOI: 10.1111/imr.13255 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 07.08.2023. Verfasst von Ye Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Adoptive cellular therapy using chimeric antigen receptor (CAR) T cells has led to a paradigm shift in the treatment of various hematologic malignancies. However, the broad application of this approach for myeloid malignancies and solid cancers has been limited by the paucity and heterogeneity of target antigen expression, and lack of bona fide tumor‐specific antigens that can be targeted without cross‐reactivity against normal tissues. This may lead to unwanted on‐target off‐tumor toxicities that could undermine the desired antitumor effect. Recent advances in synthetic biology and genetic engineering have enabled reprogramming of immune effector cells to enhance their selectivity toward tumors, thus mitigating on‐target off‐tumor adverse effects. In this review, we outline the current strategies being explored to improve CAR selectivity toward tumor cells with a focus on natural killer (NK) cells, and the progress made in translating these strategies to the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Ye Li, Katayoun Rezvani, Hind Rafei
Förderung
- NIH HHS
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- Stand Up To Cancer
Zitieren
APA
Li, Y., Rezvani, K., & Rafei, H. (2023). Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer. Immunological Reviews, 320(1), 217-235. https://doi.org/10.1111/imr.13255
Vancouver
Li Y, Rezvani K, Rafei H. Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer. Immunological Reviews. 2023;320(1):217-235. doi:10.1111/imr.13255
BibTeX
@article{Li2023,
author = {Li, Ye and Rezvani, Katayoun and Rafei, Hind},
title = {Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer},
journal = {Immunological Reviews},
year = {2023},
volume = {320},
number = {1},
pages = {217--235},
doi = {10.1111/imr.13255}
}
EUVIMED